The Medicines Company

Melinta Therapeutics, Inc.

Dario Lehoux

Thomas R Parr, Jr

Gregory Moeck

Simon Baines

Mark Harvey Wilcox

Thomas R Parr

Pierre Etienne

Sylvain Beaulieu

Geoffrey Mckay

Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.

Methods of treatment using single doses of oritavancin

The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.

Methods of treating bacterial infections using oritavancin

Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form ofandspores. Methods for the treatment, prophylaxis and prevention ofinfection and disease in animals, including humans, are described.

[object Object]

Method of inhibiting clostridium difficile by administration of oritavancin

Growing community of inventors

Terrebonne, Canada

Dario Lehoux